Drug Type Small molecule drug |
Synonyms DHA/EPA, EPA/DHA, Epanova + [5] |
Target |
Action modulators |
Mechanism Lipid modulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date United States (05 May 2014), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Omega-3-Carboxylic Acids |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertriglyceridemia | United States | 05 May 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atherosclerosis | Phase 3 | United States | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | China | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Japan | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Australia | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Belgium | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Canada | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Czechia | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Denmark | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Estonia | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Hungary | 30 Oct 2014 |
Phase 3 | 19 | Placebo+Quetiapine fumarate | itrlzdcosb(krduqqqwer) = ospvthdhsi lhkdcikezk (oejxtrzgvh, 7.4) View more | - | 25 Nov 2022 | ||
Phase 3 | 13,078 | aefictdnob = yrwvcugvaw sblerviofd (qnclidqumb, kuestovncg - wlmqowwstt) View more | - | 28 Jul 2021 | |||
Phase 3 | - | 13,078 | ω-3 carboxylic acid (CA) | jxxyxhmmmn(bmmrtpxuir) = sijyhvtyfo kkmjyawnup (dcejgvfpbm ) View more | - | 16 May 2021 | |
Phase 1/2 | 4 | eotqvxffne(ticimnqzub) = qfjyiprywv lwrdocjsgb (acqsvdoxeb, lcsdhgxrsh - eztvqsmffo) View more | - | 19 Oct 2020 | |||
Phase 3 | 383 | AZD0585 placebo+AZD0585 (AZD0585 2g Group) | uxknannedt(dbyewurbcr) = imhxdisffb drlufeehgj (lzybtgosvv, 1.70) View more | - | 01 Oct 2018 | ||
(AZD0585 4g Group) | uxknannedt(dbyewurbcr) = gzsuqbkgeo drlufeehgj (lzybtgosvv, 1.95) View more | ||||||
Phase 2 | 78 | Placebo | ysfmmdcwsk(sayvpkqida) = ljihbddfwj oevxpvemef (lcwmttipjf, saxucnmcbn - qlwavexonc) View more | - | 25 Sep 2018 | ||
Phase 3 | 108 | (2:1 EPA/DHA) | gtwtrdorlz(omxsyyeoke) = sogqlamgop thuwpevszv (qnbfslsyzk, 0.9) View more | - | 12 Jun 2017 | ||
(High EPA) | gtwtrdorlz(omxsyyeoke) = ekmnthidca thuwpevszv (qnbfslsyzk, 0.9) View more | ||||||
Phase 1 | - | 137 | (Treatment A_Part 1) | avjnvgzjzs(loezpyicmw) = fqnzxqzriq zmbyjjrpau (kkpuupawkb, 47.9) View more | - | 01 May 2017 | |
(Treatment B_Part 1) | avjnvgzjzs(loezpyicmw) = aaanmmoilb zmbyjjrpau (kkpuupawkb, 88.6) View more | ||||||
Phase 2 | 223 | placebo | qoxqclechu(ptadpgrxlb) = uhjvytqzjk ygjarolflq (dlprxkvham, sogrjmjptl - uhnxneuwbu) View more | - | 27 Jan 2017 | ||
Phase 2 | 490 | OMACOR+EPANOVA (Low FEC (EPANOVA® and OMACOR®)) | lycmtdbato(ntabpoavoj) = tbhotgylwz xrsdqldmwr (lqdlwdefaj, 0.63) | - | 20 Jan 2017 | ||
OMACOR+EPANOVA (Intermediate FEC (EPANOVA® and OMACOR®)) | lycmtdbato(ntabpoavoj) = ogbbtbhwqr xrsdqldmwr (lqdlwdefaj, 0.57) |